Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention

The Prostate Cancer Prevention Trial (PCPT) demonstrated a risk of prostate cancer at prostate-specific antigen (PSA) < 4.0 ng/ml and that prostate cancer risk is reduced by finasteride. A major concern about early detection by PSA and prevention by finasteride is that they may involve biological...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lucia, M. Scott, Darke, Amy K., Goodman, Phyllis J., Tangen, Catherine M., Rosa, Francisco G. La, Parnes, Howard L., Ford, Leslie G., Coltman, Charles A., Thompson, Ian M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2008
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3985428/
https://ncbi.nlm.nih.gov/pubmed/19138952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-08-0078
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak